At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research
Adaptive Biotechnologies announced that its clonoSEQ MRD test will be featured in 33 presentations at the ASCO and EHA 2026 conferences, including 14 oral presentations and one plenary session. The data presented reinforces clonoSEQ’s position as the gold standard for measurable residual disease assessment across multiple hematologic malignancies, including multiple myeloma, CLL, and lymphoma.
Key figures
- Plenary sessions
- 1
- Sensitivity ratio
- 1 in 1,000,000
- Oral presentations
- 14
- Total presentations
- 33
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.